Analyst firms · BofA Securities · AKRO
BofA Securities AKRO price target and rating history
Akero Therapeutics Inc. (AKRO) · Health Care
BofA Securities rates Akero Therapeutics Inc. (AKRO) Buy with a $63 price target, as of its latest action on Jan 30, 2025. It has published 3 rating actions on AKRO since September 2021, including 1 upgrade and 0 downgrades.
- Current rating
- Buy
- Price target
- $63
- Median target, all firms
- Too few
- Actions on AKRO
- 3
BofA Securities price target on AKRO
Every BofA Securities rating on AKRO
- Jan 30, 2025
- Apr 22, 2024
- Sep 10, 2021
Questions about BofA Securities and AKRO
- What is BofA Securities's price target for AKRO?
- BofA Securities's latest stated price target for Akero Therapeutics Inc. (AKRO) is $63, from its action on Jan 30, 2025.
- What is BofA Securities's rating on AKRO?
- BofA Securities rates AKRO Buy, a bullish rating, as of Jan 30, 2025.
- When did BofA Securities last change its view on AKRO?
- On Jan 30, 2025, BofA Securities upgrades to Buy from Neutral, price target $35 to $63.
More AKRO rating histories
All BofA Securities ratingsAKRO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.